Donal P. Mclornan

250 Euston Road
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 223 publications

Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global ComMittee.

Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global ComMittee.

Journal: Bone marrow transplantation

Published: June 08, 2026

The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022.

The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022.

Journal: British journal of haematology

Published: May 15, 2026

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease-directed progress.

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease-directed progress.

Journal: British journal of haematology

Published: April 17, 2026

Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes harboring a paroxysmal nocturnal hemoglobinuria clone-a study on behalf of the Chronic Malignancies and Severe Aplastic Anemia Working Parties of the EBMT.

Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes harboring a paroxysmal nocturnal hemoglobinuria clone-a study on behalf of the Chronic Malignancies and Severe Aplastic Anemia Working Parties of the EBMT.

Journal: Bone marrow transplantation

Published: April 15, 2026

Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM Trials.

Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM Trials.

Journal: European journal of haematology

Published: April 10, 2026

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy.

Journal: Bone marrow transplantation

Published: March 27, 2026

Trends in Transplantation for Myelodysplastic Syndrome Patients Across Recent Decades: A Registry-Based Study on Behalf of the Chronic Malignancies Working of the EBMT.

Trends in Transplantation for Myelodysplastic Syndrome Patients Across Recent Decades: A Registry-Based Study on Behalf of the Chronic Malignancies Working of the EBMT.

Journal: American journal of hematology

Published: March 09, 2026

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

Journal: British journal of haematology

Published: February 25, 2026

Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee.

Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee.

Journal: Bone marrow transplantation

Published: February 18, 2026

Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation.

Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation.

Journal: American journal of hematology

Published: February 03, 2026

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Journal: The Lancet. Haematology

Published: January 12, 2026

Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1.

Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1.

Journal: Clinical lymphoma, myeloma & leukemia

Published: December 18, 2025

Showing 1-12 of 223

Last Updated: 09/26/2026